Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of cabazitaxel on metastatic bone disease in castration-resistant prostate cancer
2016-001253-41Phase 2Completed
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Feb 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in prostate cancer (PCa), sponsored by Gruppo Oncologico dell'Italia Meridionale. Primary endpoint: Bone (Skeletal) progression-free survival. Started Feb 2021; status: completed.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-001253-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001253-41.